IMA-203 is under clinical development by Immatics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMA-203’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMA-203 is under development for the treatment of solid tumors include hepatocellular carcinoma ovarian cancer, endometrial cancer, uterine cancer, sqNSCLC, subtypes of synovial sarcoma, uveal melanoma. It is based on XPRESIDENT, ACTengine platform and XCEPTOR platfom. XPRESIDENT is a target discovery engine which identifies tumor-associated peptides (TUMAPs) / T-cell targets. ACTengine platform uses autologous T-cells which are genetically engineered to express T-cell receptors upon lentiviral transduction which recognise targets identified by XPRESIDENT. These cells are expanded ex-vivo and reinfused back into the patient.It acts by targeting cells expressing preferentially expressed antigen in melanoma (PRAME).It is administered through intravenous route.
Immatics is a biopharmaceutical company focused on the development of T cell immunotherapies to fight against cancer. Immatics is headquartered in Tuebingen, Germany.
For a complete picture of IMA-203’s drug-specific PTSR and LoA scores, buy the report here.